ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
BUB1B is a novel prognostic-related biomarker and correlated with immune infiltrates in lung adenocarcinoma.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe BUB1 mitotic checkpoint serine/threonine kinase B (BUB1B), one of the core proteins of the spindle checkpoint, has been linked to a poor prognosis in many tumors. Our purpose was to explore the clinical value and biological function of BUB1B in lung adenocarcinoma (LUAD).
methodsTCGA Level 3 RSEM-normalized RNA-seq data, GTEx standardized expression data, TIMER (for purity-corrected immune infiltration estimation), and single-sample gene set enrichment analysis (ssGSEA) (using the GSVA R package with method = "ssgsea") were used to analyze BUB1B expression, prognosis, immune infiltration in LUAD. The role of BUB1B in H1650 and A549 cells was investigated through knocking-down BUB1B or overexpression BUB1B.
resultsBUB1B expression was significantly increased in LUAD tissues. High levels of BUB1B indicated a worse outcome. BUB1B expression was closely linked to tumor size and TMN stage, which was an independent risk factor for the prognosis of LUAD. BUB1B was associated with 20 types of TIICs as determined by ssGSEA analysis of 28 immune cell signatures. In TIMER database, BUB1B showed a positive correlation with neutrophil infiltration, but negatively correlated with immune infiltration levels of B cells and CD4 + T cells. These findings were cross-validated across TIMER, ssGSEA, and GEPIA platforms. Low dendritic cell infiltration, low B cell infiltration, and high expression of BUB1B were closely linked to lower cumulative survival in patients with LUAD. BUB1B overexpression augmented the proliferation, invasion and migration of A549 and H1650 cells, reduced the apoptosis, and promoted the EMT process. Whereas, BUB1B knockdown showed the opposite results. Additionally, BUB1B overexpression promoted macrophage recruitment by regulating CCL2 and p-P65 expression, as confirmed by in vitro Transwell chemotaxis assays using THP-1-derived macrophages.
conclusionsBUB1B may be a critical factor in regulating immune function and may serve as a novel clinical prognostic marker of LUAD patients.
Indexed as
Identifiers
42295646What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.